Determine the necessary mass, volume, or concentration for preparing a solution.
para flujos de trabajo cromatográficos y analíticos sensibles que requieren una interferencia mínima de la línea base.
Store at -20°C Envío Ice chest + Ice pads. Consulte el COA específico del lote para conocer las especificaciones exactas.
SDS, COA, ficha técnica y hoja de especificaciones disponibles para descargar. COA específico del lote accesible mediante búsqueda por número de lote.
Citado en 0 publicaciones revisadas por pares sobre cromatografía, síntesis orgánica y reacciones de acoplamiento cruzado.
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti- CD3 and anti- B cell maturation antigens ( BCMA ). Pavurutamab has an extended half-life based on Pacanalotamab . The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM)
In Vitro
Pavurutamab (0-10000 pM; 48 h) induces CD69 + , CD25 + T cell activation and IFNγ, TNFα, IL-2, IL-4, IL-6, IL-10 cytokine secretion . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Pavurutamab (0.02, 0.2 and 2 mg/kg; i.v.; single dose on days 3, 8, 13) reduces tumor volume with time and dose dependent manner in mouse xenograft models. Pavurutamab (0.005, 0.05 and 0.5 mg/kg; i.v.; every 5 days for 6 administrations, lasting for 30 days) reduces tumor volume and increases survival with time and dose dependent manner in NOD/SCID mice transplanted with L-363 multiple myeloma (MM) cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female NOD/SCID mice transplanted with NCI-H929 MM cells mixed with PBMCs. Dosage: 0.02, 0.2 and 2 mg/kg. Administration: Intravenous injection; single dose on days 3, 8, 13. Result: Reduced tumor volume. Animal Model: NOD/SCID mice orthotopically transplanted with L-363 MM cells. Dosage: 0.005, 0.05 and 0.5 mg/kg. Administration: Intravenous injection; every 5 days for 6 administrations, starting from day 9 and lasting for 30 days. Result: Reduced tumor volume and increased survival.
IC50& Target:B cell maturation antigens, BCMA
Documento completo sobre peligros, manipulación, almacenamiento y cumplimiento normativo.
<<<<<<< HEAD Descargar SDS → ======= Descargar SDS → >>>>>>> release248-p3Datos de calidad específicos del lote. Introduzca su número de lote para obtener el COA exacto.
Buscar COA →Resumen de referencia rápida de las especificaciones y aplicaciones del producto.
Ver ficha técnica →Atributos de calidad completos y criterios de aceptación para esta calidad.
Ver hoja de especificaciones →